Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for KYNB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 19.25M
December 31, 2025 19.56M
September 30, 2025 21.04M
June 30, 2025 93.13M
March 31, 2025 91.22M
December 31, 2024 90.21M
September 30, 2024 91.68M
June 30, 2024 148.25M
March 31, 2024 153.38M
December 31, 2023 154.86M
September 30, 2023 158.64M
June 30, 2023 162.59M
March 31, 2023 94.16M
December 31, 2022 96.68M
September 30, 2022 96.51M
June 30, 2022 99.52M
March 31, 2022 103.32M
December 31, 2021 106.40M
September 30, 2021 109.41M
June 30, 2021 112.50M
March 31, 2021 55.99M
December 31, 2020 57.27M
September 30, 2020 59.93M
June 30, 2020 62.34M
Date Value
March 31, 2020 65.20M
December 31, 2019 62.62M
September 30, 2019 71.49M
June 30, 2019 74.38M
March 31, 2019 76.70M
December 31, 2018 107.96M
September 30, 2018 114.27M
June 30, 2018 114.45M
March 31, 2018 115.44M
December 31, 2017 109.11M
September 30, 2017 114.29M
June 30, 2017 113.74M
March 31, 2017 112.69M
December 31, 2016 107.31M
September 30, 2016 113.12M
June 30, 2016 112.91M
March 31, 2016 112.86M
December 31, 2015 107.33M
September 30, 2015 112.42M
June 30, 2015 112.12M
March 31, 2015 111.65M
December 31, 2014 108.69M
September 30, 2014 114.07M
June 30, 2014 96.91M
March 31, 2014 96.86M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Vericel Corp. 80.41M
Capricor Therapeutics, Inc. 89.56M
ARS Pharmaceuticals, Inc. 96.68M
ACADIA Pharmaceuticals, Inc. 59.55M
Alnylam Pharmaceuticals, Inc. 2.942B